Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

755
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
755
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

574
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
574
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

536
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
536
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

663
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
663
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

479
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
479
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

664
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
664

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

The Rome V criteria for the diagnosis of irritable bowel syndrome in secondary care: a diagnostic accuracy study.

The lancet. Gastroenterology & hepatology·2026
Same author

The Challenges of Performing Controlled Trials of Diet Therapies in Gastroenterology.

JGH open : an open access journal of gastroenterology and hepatology·2026
Same author

Efficacy of gut-brain neuromodulators and brain-gut behaviour therapies for irritable bowel syndrome: systematic review and network meta-analysis.

Gut·2026
Same author

Belief of Allocated Treatment and Symptom Response to Amitriptyline in Irritable Bowel Syndrome.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Recommendations for the Evaluation and Management of Inflammatory Bowel Disease With Irritable Bowel Syndrome-Like Symptoms: A Joint Rome Foundation and International Organization for the Study of IBD (IOIBD) Consensus.

Gastroenterology·2026
Same author

Design of Treatment Trials for Disorders of Gut-Brain Interaction.

Gastroenterology·2026
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Dec 6, 2025

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
10:37

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

8.6K

刺激性腸症候群

Alexander C Ford1, Ami D Sperber2, Maura Corsetti3

  • 1Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK; Leeds Gastroenterology Institute, St James's University Hospital, Leeds, UK.

Lancet (London, England)
|October 13, 2020
PubMed
まとめ
この要約は機械生成です。

刺激性腸症候群 (IBS) は,腹痛と腸の習慣の変化を特徴とする一般的な機能的胃腸疾患です. 腸-脳軸の病理生理学を理解することで 患者の治療結果を改善する 標的型治療法を開発できます

さらに関連する動画

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.4K
Diagnosis of Hirschsprung's Disease by Immunostaining Rectal Suction Biopsies for Calretinin, S100 Protein and Protein Gene Product 9.5
05:45

Diagnosis of Hirschsprung's Disease by Immunostaining Rectal Suction Biopsies for Calretinin, S100 Protein and Protein Gene Product 9.5

Published on: April 26, 2019

13.9K

関連する実験動画

Last Updated: Dec 6, 2025

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
10:37

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

8.6K
Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.4K
Diagnosis of Hirschsprung's Disease by Immunostaining Rectal Suction Biopsies for Calretinin, S100 Protein and Protein Gene Product 9.5
05:45

Diagnosis of Hirschsprung's Disease by Immunostaining Rectal Suction Biopsies for Calretinin, S100 Protein and Protein Gene Product 9.5

Published on: April 26, 2019

13.9K

科学分野:

  • 胃腸内科
  • 神経胃腸内科
  • 機能的胃腸疾患

背景:

  • 刺激性腸症候群 (IBS) は,5-10%の健康な個人に影響し,腹痛と便の形態/頻度の変化を示します.
  • 危険因子には腸内感染症,心理的な併発症,若い女性の高い罹患率が含まれます.
  • 病理生理学には 腸-脳軸の機能不全があり 運動能力の問題や 内臓過敏症や 中枢神経系の処理が変化します

研究 の 目的:

  • 刺激性腸症候群 (IBS) の病理生理学に関する現在の理解をレビューする.
  • IBSの診断方法と管理戦略を概説する.
  • IBSの新たな治療法の発展を強調する.

主な方法:

  • IBSの病理生理学,診断,治療に関する既存の文献のレビュー.
  • 危険因子と疫学データの分析
  • 現在の治療法と新しい治療法の検討

主要な成果:

  • IBSの診断は 病歴に依拠し 警報症状を慎重に調べます
  • 管理は患者の教育,食事の変更,繊維,抗薬に焦点を当てています.
  • 先進的な治療は,神経調節薬,受容体特異薬,心理療法を用いて重症症状を標的としています.

結論:

  • 効果的なIBS管理には 共感的なアプローチが必要で 生活の質を向上させ 医療費を削減します
  • 腸-脳軸はIBSの病理生理学の中心であり,進行中の研究により新しい薬候補が得られます.
  • 最近の病理学的洞察に基づいて,新しいIBS治療法のパイプラインが増加すると予想されています.